These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 8757209)

  • 1. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial.
    Bernstein IL; Bernstein DI; Dubb JW; Faiferman I; Wallin B
    J Allergy Clin Immunol; 1996 Aug; 98(2):317-24. PubMed ID: 8757209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auranofin in the treatment of steroid dependent asthma: a double blind study.
    Nierop G; Gijzel WP; Bel EH; Zwinderman AH; Dijkman JH
    Thorax; 1992 May; 47(5):349-54. PubMed ID: 1609377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
    Kishiyama JL; Valacer D; Cunningham-Rundles C; Sperber K; Richmond GW; Abramson S; Glovsky M; Stiehm R; Stocks J; Rosenberg L; Shames RS; Corn B; Shearer WT; Bacot B; DiMaio M; Tonetta S; Adelman DC
    Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open study of auranofin in the treatment of steroid-dependent asthma.
    Bernstein DI; Bernstein IL; Bodenheimer SS; Pietrusko RG
    J Allergy Clin Immunol; 1988 Jan; 81(1):6-16. PubMed ID: 3276761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma.
    Nelson HS; Busse WW; deBoisblanc BP; Berger WE; Noonan MJ; Webb DR; Wolford JP; Mahajan PS; Hamedani AG; Shah T; Harding SM
    J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):267-75. PubMed ID: 9949318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
    Knorr B; Franchi LM; Bisgaard H; Vermeulen JH; LeSouef P; Santanello N; Michele TM; Reiss TF; Nguyen HH; Bratton DL
    Pediatrics; 2001 Sep; 108(3):E48. PubMed ID: 11533366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.
    Wechsler ME; Colice G; Griffiths JM; Almqvist G; Skärby T; Piechowiak T; Kaur P; Bowen K; Hellqvist Å; Mo M; Garcia Gil E
    Respir Res; 2020 Oct; 21(1):264. PubMed ID: 33050928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Pulmicort Turbuhaler Study Group.
    Nelson HS; Bernstein IL; Fink J; Edwards TB; Spector SL; Storms WW; Tashkin DP
    Chest; 1998 May; 113(5):1264-71. PubMed ID: 9596304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.
    Menzies-Gow A; Gurnell M; Heaney LG; Corren J; Bel EH; Maspero J; Harrison T; Jackson DJ; Price D; Lugogo N; Kreindler J; Burden A; de Giorgio-Miller A; Padilla K; Martin UJ; Garcia Gil E
    Lancet Respir Med; 2022 Jan; 10(1):47-58. PubMed ID: 34619104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gold as an oral corticosteroid sparing agent in stable asthma.
    Evans DJ; Cullinan P; Geddes DM
    Cochrane Database Syst Rev; 2001; 2000(2):CD002985. PubMed ID: 11406053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma.
    Karpel JP; Nayak A; Lumry W; Craig TJ; Kerwin E; Fish JE; Lutsky B
    Respir Med; 2007 Mar; 101(3):628-37. PubMed ID: 16875813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.
    Jover JA; Hernández-García C; Morado IC; Vargas E; Bañares A; Fernández-Gutiérrez B
    Ann Intern Med; 2001 Jan; 134(2):106-14. PubMed ID: 11177313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma.
    Vogelmeier C; Kardos P; Hofmann T; Canisius S; Scheuch G; Muellinger B; Nocker K; Menz G; Rabe KF
    Eur Respir J; 2015 May; 45(5):1273-82. PubMed ID: 25504995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate in the management of severe steroid dependent asthma.
    Taylor DR; Flannery EM; Herbison GP
    N Z Med J; 1993 Sep; 106(964):409-11. PubMed ID: 8377957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
    Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
    Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma.
    Lock SH; Kay AB; Barnes NC
    Am J Respir Crit Care Med; 1996 Feb; 153(2):509-14. PubMed ID: 8564089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
    Petri MA; Lahita RG; Van Vollenhoven RF; Merrill JT; Schiff M; Ginzler EM; Strand V; Kunz A; Gorelick KJ; Schwartz KE;
    Arthritis Rheum; 2002 Jul; 46(7):1820-9. PubMed ID: 12124866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.